Improved: SALSA digitalMLPA Probemix D001 Hereditary Cancer Panel 1

Hereditary forms of cancer – one of the leading causes of mortality worldwide – account for approximately 10% of all cancer cases. Based on our latest technology, SALSA^® digitalMLPA™ Probemix D001 Hereditary Cancer Panel 1 was specifically developed to detect CNVs and other selected variants associated with a higher risk of developing eight frequent hereditary cancers: breast, ovarian, colorectal, gastric, prostate, pancreatic, endometrial and melanoma. 

D001 Hereditary Cancer Panel 1 recently received an update, with version D1 featuring several new modified probes, increasing the performance and coverage of the product. A significant improvement compared to the previous version is the addition of two new probes targeting the MSH2 exon 2–6 inversion, which accounts for a subset of unexplained Lynch syndrome cases (for more details about this inversion, see Pagnamenta et al. 2024).

With a turnaround time of only 48-72 hours and with as little as 20 ng of DNA input per reaction, SALSA^® digitalMLPA™ combines the trusted MLPA technology with the broad coverage of NGS, making the investigation of hereditary cancer variants straightforward and accessible.